Page 8 - ARNM-1-2

Advances in Radiotherapy
& Nuclear Medicine Editorial

(viii) Molecular imaging and radionuclide therapy (MI & medical community. It serves as a vital tool for professionals
RT): ARNM’s focus on MI & RT opens new realms looking to expand their knowledge and improve patient
in understanding and combating cancer at the outcomes in the rapidly evolving field of cancer treatment.
molecular level .
[5]
To expand our readership, we will continue to diversify Conflict of interest
the scope of ARNM and publish research and review articles The author declares no conflict of interest.
in various relevant fields. These esteemed works include References
clinical radiotherapy, combined modality treatment,
translational studies, epidemiological outcomes, imaging, 1. Levin-Epstein R, Cook RR, Wong JK, et al., 2020, Prostate-
dosimetry, and radiation therapy planning. Moreover, specific antigen kinetics and biochemical control following
the journal extends its scope to experimental work in stereotactic body radiation therapy, high dose rate
radiobiology, chemobiology, hyperthermia, tumor biology, brachytherapy, and low dose rate brachytherapy: A multi-
data science in radiation oncology, and the physics aspects institutional analysis of 3502 patients. Radiother Oncol,
151: 26–32.
pertinent to oncology. This diverse content ensures that
ARNM covers a vast spectrum of interest areas in radiation https://doi.org/10.1016/j.radonc.2020.07.014
oncology, offering readers a holistic view of the field. 2. Qi P, Chen Q, Tu D, et al., 2020, The potential role of
It is our aim to establish ARNM as an impetus behind borophene as a radiosensitizer in boron neutron capture
the impending change in clinical practice: ARNM is more therapy (BNCT) and particle therapy (PT). Biomater Sci,
8: 2778–2785.
than just a journal; it is a catalyst for transformation,
consistently introducing new ideas and perspectives that https://doi.org/10.1039/D0BM00318B
revolutionize radiation oncological clinical practice. Its 3. Jhawar SR, Rivera-Núñez Z, Drachtman R, et al., 2019,
dedication to disseminating novel research empowers Association of combined modality therapy vs chemotherapy
professionals to stay at the forefront of the field, ensuring alone with overall survival in early-stage pediatric Hodgkin
that patient care is always informed by the latest and most lymphoma. JAMA Oncol, 5: 689–695.
efficacious strategies. https://doi.org/10.1001/jamaoncol.2018.5911
ARNM stands as a budding testament to the unyielding 4. Sachpekidis C, Goldschmidt H, Dimitrakopoulou-
pursuit of excellence in oncological care. Its influential role Strauss A, 2019, Positron emission tomography (PET)
in shaping the future of cancer treatment is undeniable, radiopharmaceuticals in multiple myeloma. Molecules,
offering hope and new horizons in the journey toward 25: 134.
conquering cancer. As ARNM continues to illuminate https://doi.org/10.3390/molecules25010134
the path forward, it reaffirms the medical community’s 5. Taïeb D, Jha A, Treglia G, et al., 2019, Molecular imaging
dedication to saving lives and improving the quality of life and radionuclide therapy of pheochromocytoma and
for cancer patients worldwide. paraganglioma in the era of genomic characterization of
With its extensive coverage and commitment to disease subgroups. Endocr Relat Cancer, 26: R627–R652.
innovation, ARNM not only educates but also inspires the https://doi.org/10.1530/ERC-19-0165

Volume 1 Issue 2 (2023) 2 https://doi.org/10.36922/arnm.2615